SRR975564
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- MYC_TARGETS_V1+0.570
- MYC_TARGETS_V2+0.560
- E2F_TARGETS+0.530
- G2M_CHECKPOINT+0.470
- MTORC1_SIGNALING+0.470
- UNFOLDED_PROTEIN_RESPONSE+0.450
- GLYCOLYSIS+0.370
- OXIDATIVE_PHOSPHORYLATION+0.360
- INFLAMMATORY_RESPONSE+0.340
- TNFA_SIGNALING_VIA_NFKB+0.330
Top 10 suppressed
- HEDGEHOG_SIGNALING-0.440
- BILE_ACID_METABOLISM-0.330
- INTERFERON_ALPHA_RESPONSE-0.310
- WNT_BETA_CATENIN_SIGNALING-0.260
- HEME_METABOLISM-0.150
- TGF_BETA_SIGNALING-0.150
- COAGULATION-0.140
- XENOBIOTIC_METABOLISM-0.140
- UV_RESPONSE_DN-0.130
- KRAS_SIGNALING_DN-0.110
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
10 twins match this tumor's tissue · 0 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MNG732 | — | — | 0.846 |
| 2 | A07BA2E1-CCA0-4231-A391-B13383A2BCB9 | — | — | 0.839 |
| 3 | 37784b02-1e45-4806-b4c3-2b3ad50dbfb3 | — | — | 0.833 |
| 4 | SRR6013603 | — | cohortA3 | 0.825 |
| 5 | MNG654 | — | — | 0.820 |
| 6 | X11368e6c.aeb6.4de4.8e74.436b1cd1846c | — | cohortA1 | 0.818 |
| 7 | SRR8518152 | — | E | 0.805 |
| 8 | MNG1082 | — | — | 0.801 |
| 9 | TCGA-66-2759-01A-01R-0851-07 | — | cohortSQ2 | 0.799 |
| 10 | 109ABE6B-033D-47E8-A03A-D285BE82C17B | — | — | 0.798 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 31 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| MYC_TARGETS_V1 | 0.570 | Inavolisib | — uncovered |
| MYC_TARGETS_V2 | 0.560 | Idelalisib | — uncovered |
| E2F_TARGETS | 0.530 | Inavolisib | — uncovered |
| G2M_CHECKPOINT | 0.470 | Inavolisib | — uncovered |
| MTORC1_SIGNALING | 0.470 | Inavolisib | — uncovered |
| UNFOLDED_PROTEIN_RESPONSE | 0.450 | Idelalisib | — uncovered |
| GLYCOLYSIS | 0.370 | Inavolisib | — uncovered |
| OXIDATIVE_PHOSPHORYLATION | 0.360 | Remibrutinib | — uncovered |
| INFLAMMATORY_RESPONSE | 0.340 | Idelalisib | — uncovered |
| TNFA_SIGNALING_VIA_NFKB | 0.330 | Inavolisib | — uncovered |
| ALLOGRAFT_REJECTION | 0.240 | Idelalisib | — uncovered |
| DNA_REPAIR | 0.230 | Idelalisib | — uncovered |
| ANGIOGENESIS | 0.220 | Remibrutinib | — uncovered |
| HYPOXIA | 0.220 | Idelalisib | — uncovered |
| REACTIVE_OXYGEN_SPECIES_PATHWAY | 0.210 | Inavolisib | — uncovered |
| CHOLESTEROL_HOMEOSTASIS | 0.200 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.180 | Inavolisib | — uncovered |
| P53_PATHWAY | 0.150 | Idelalisib | — uncovered |
| ADIPOGENESIS | 0.140 | Inavolisib | — uncovered |
| APOPTOSIS | 0.140 | Idelalisib | — uncovered |